Elevated Lipoprotein(a) Clinical Trial
Official title:
A Randomized, Double Blind, Placebo-Controlled, Dose Titration, Phase 2 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 494372 Administered Subcutaneously to Patients With High Lipoprotein(a)
The purpose is to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of ISIS-APO(a)Rx given to participants with high lipoprotein(a) for 12 weeks.
Lipoprotein(a) [Lp(a)] is a genetic variant of low-density lipoprotein (LDL) in which the
apolipoprotein B (apoB) -100 component of LDL is linked by a disulfide bond to
apolipoprotein(a) [apo(a)], the distinct protein component of Lp(a) that is mainly
responsible for its signature structural and functional properties. Lp(a) is now recognized
as an important genetic risk factor for coronary artery disease, stroke and aortic stenosis.
The purpose of this study is to determine if ISIS-APO(a)Rx can reduce the production of
apolipoprotein(a), or apo(a). This study will enroll 50 participants with Lipoprotein(a) ≥50
and <175 mg/dL and 10 participants with Lipoprotein(a) ≥175 mg/dL.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03070782 -
Phase 2 Study of ISIS 681257 (AKCEA-APO(a)-LRx) in Participants With Hyperlipoproteinemia(a) and Cardiovascular Disease
|
Phase 2 | |
| Completed |
NCT03392051 -
Drug-drug Interaction Study to Evaluate the Effect of ISIS 681257 on Clopidogrel
|
Phase 1 | |
| Completed |
NCT03426033 -
Drug-drug Interaction Study to Evaluate the Effect of ISIS 681257 on Warfarin
|
Phase 1 | |
| Completed |
NCT02414594 -
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS APO(a)-LRx in Healthy Volunteers With Elevated Lipoprotein(a)
|
Phase 1 |